Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has submitted its application to the U.S. Food and Drug Administration (FDA) requesting Breakthrough Device Designation for its non-invasive Next Generation colorectal cancer (CRC) product including the Company’s novel portfolio of mRNA biomarkers. Subject to the FDA’s review, a Breakthrough Device Designation could significantly accelerate approval.
Heavy alcohol use linked to increased risk of Type 2 diabetes in middle-aged adults
Heavy alcohol use may increase middle-aged adults’ risk of developing Type 2 diabetes, according to research to be presented this week at the American Physiology
April 7, 2024